Tralokinumab for eczema with genital symptoms
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial tests if tralokinumab, a drug already approved for moderate-to-severe eczema, helps people who also have eczema in the genital area. It aims to understand how well the drug works for this specific symptom.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have moderate to severe eczema that also affects your genital area.
- Your doctor has already decided to start you on tralokinumab as part of your normal care.
- You are able to give informed consent and follow the study instructions.
- You are not pregnant or nursing, and you are not taking part in any other study with experimental treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks pregnancy and baby outcomes in people who have been pregnant while taking tralokinumab, a medication for eczema. It compares those outcomes to other eczema treatment groups to help doctors understand potential risks or reassuring effects.
This study tests an investigational shot (tralokinumab) plus a steroid cream for children with moderate-to-severe eczema that hasn't been controlled by creams alone. It aims to see if the combination is safe and works better than the cream alone.
This trial tests an investigational drug called TRB-061 in healthy adults and people with atopic dermatitis (eczema). It aims to see if the drug is safe and how the body processes it. If you have moderate to severe eczema that started at least a year ago, you may be able to join the patient part of the study.
This study tests a new medication called camoteskimab for adults with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to creams alone. The drug works by targeting a protein in the body that causes eczema symptoms like itching and inflammation.
This trial tests an oral medication called ICP-332 for adults with moderate to severe eczema (atopic dermatitis) who haven't gotten enough relief from topical creams. It aims to see if the drug can reduce skin inflammation and itching.
This study tests a cream called trilinolein to see if it can prevent eczema from coming back in people whose skin is currently clear or nearly clear. If you have had moderate-to-severe eczema and are in a quiet phase, this treatment might help you stay symptom-free longer.
Hear when a new Atopic Dermatitis (Moderate-to-severe) Involving the Genital Region trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.